

CRISPR Chronicles: Advancing Gene Editing in Cardiovascular Treatment

Sahlan Abdullah Rohim

Departement of Pharmacy, Beni-Suef University, Egypt

ABSTRACT

CRISPR-Cas technologies have transformed gene editing, providing accurate and effective genome alterations with extensive implications in biological research and treatment strategies. This technology has eclipsed conventional techniques, including zinc-finger nucleases (ZFNs) and transcription activator-like effector nucleases (TALENs), owing to its simplicity, cost-efficiency, and superior precision. In cardiovascular disease (CVD) research, CRISPR has been essential in creating accurate disease models, pinpointing genetic risk factors, and formulating possible therapeutic approaches. Genome editing has facilitated the rectification of monogenic mutations associated with inherited cardiomyopathies and arrhythmias while also addressing metabolic risk factors like PCSK9 to mitigate atherosclerosis. Innovations including base editing, prime editing, and RNA editing have augmented CRISPR's accuracy, reducing off-target effects and enhancing therapeutic relevance. Delivery modalities, encompassing adeno-associated viral (AAV) vectors and nanoparticle-based approaches, have been refined to improve efficacy and safety. Notwithstanding these advancements, difficulties, including inadvertent genetic alterations, immunological reactions, and ethical dilemmas surrounding germline editing, remain. The effective clinical implementation of CRISPR therapeutics necessitates additional refinement, stringent validation, and regulatory supervision to guarantee safety and efficacy. Ongoing research indicates that CRISPR-based genome editing possesses significant advantages for improving cardiovascular treatment. Advancements in delivery methods, enhanced precision in gene editing, and ethical considerations will be pivotal in the incorporation of CRISPR into

Received: 2024-09-09 Revised: 2025-01-10 Accepted: 2025-03-01 Published: 2025-06-30

clinical practice. Through ongoing advancement, CRISPR possesses the capacity to emerge as a revolutionary therapeutic instrument, providing accurate and enduring remedies for cardiovascular diseases and many genetic problems.

Keywords: Cardiovascular Diseases, Genome Editing, Gene Therapy.

INTRODUCTION

The advent of CRISPR-Cas systems has significantly transformed the field of gene editing, including applications in research, biotechnology, and potential clinical treatments for disease management. This technology, characterized by design simplicity, cost-effectiveness, rapid execution, and unmatched precision and effectiveness, has surpassed previous methods such as editing zinc-finger nucleases (ZFNs) and transcription activator-like effector nucleases (TALENs) [1]. Recently, CRISPR-Cas technologies have proved pivotal in facilitating genome changes in several taxa, including human cells, primates, murine models, zebrafish, *Bombyx mori*, and microbes [2]. This technological innovation has initiated significant breakthroughs in preclinical and clinical research, especially for treating resistant disorders. Monogenic genetic illnesses constitute a notable category of human ailments that have been addressed in preclinical and clinical trials utilizing CRISPR-Cas technology to amend their genetic foundations. Furthermore, disorders with complex genetic origins may also gain from the accuracy of CRISPR-mediated genetic correction. In addition to genetic abnormalities, the adaptability of CRISPR-Cas encompasses the treatment of infectious diseases, autoimmune disorders, and cancer. Significant achievements encompass the first ex vivo clinical trial in 2018 employing CRISPR-Cas9-modified cells for cancer therapy, succeeded by the U.S. approval of the initial in vivo clinical trial by the Food and Drug Administration in 2019. The growing database of clinical studies, as recorded on platforms such as ClinicalTrials.gov, highlights the increasing interest in this novel technology. However, the use of CRISPR-Cas technologies as effective therapeutic options requires the resolution of various problems essential for their safe and effective use in different clinical settings.

The CRISPR system consists of a CRISPR-associated (Cas) endonuclease coupled with a specifically designed single guide RNA (sgRNA) to target a particular DNA sequence. Cas nucleases are enzymes that bind to DNA and make double-stranded breaks. The sgRNA features a bifunctional architecture: a scaffold region that interacts with the Cas protein and a customizable sequence intended to direct the Cas protein to a specific genomic location. This versatility enables CRISPR technology to precisely target nearly any genomic area by simple alterations of the sgRNA nucleotide sequence, facilitating the repair of harmful mutations or the silencing of genes associated with disease pathogenesis [3]. The range of CRISPR applications is vast, including gene function disruption (knockout), introduction of new genetic functions (knock-in), activation or suppression of endogenous genes, and integration into genomic diagnostic techniques. Advanced versions of CRISPR, including base editing and prime editing, utilize modified Cas enzymes to achieve precise single-nucleotide modifications in the genome without requiring double-stranded DNA cleavage. In addition to genome editing, CRISPR demonstrates potential for gene modulation via approaches such as CRISPRa (gene activation) and CRISPRi (gene suppression). By targeting modified sgRNA-Cas complexes to gene promoter regions, these methods enable the recruitment of transcriptional activators to augment gene expression or repressors to diminish it, thereby allowing precise control over gene regulation. Despite its transformational potential, the therapeutic application of CRISPR-Cas technology is still in its early phases. Currently, just 89 clinical trials utilizing CRISPR are in progress, highlighting the significant translational efforts needed to actualize its potential as a therapeutic approach. Challenges, including accidental genomic alterations and the uncertain long-term ramifications of CRISPR interventions, pose substantial challenges. Nonetheless, the unique benefits provided by this technology suggest that these obstacles will be overcome, leading to its incorporation into sophisticated healthcare systems in the near future.

RESEARCH LABORATIONS

CRISPR-Cas systems are classified according to variations in their core Cas proteins, grouped into two principal classes (1 and 2) and then segmented into six categories (I–VI) with distinct subtypes. Class 1 systems depend on multi-Cas protein complexes and encompass Type I, which utilizes Cas3 to target DNA; Type III, which employs Cas10 to target both DNA and

Received: 2024-09-09 Revised: 2025-01-10 Accepted: 2025-03-01 Published: 2025-06-30

RNA; and Type IV, whose mechanisms, although linked to the DinG enzyme, are predominantly obscure. On the other hand, Class 2 systems only use one Cas protein. Type II uses Cas9 to target DNA, Type V uses Cas12 and Cas14 to target DNA, and Type VI only uses Cas13 to edit RNA. Types I, II, and V concentrate on DNA; Type III addresses both DNA and RNA; and Type VI is exclusive to RNA. Guided by RNA, CRISPR-Cas systems facilitate various genetic modifications, including gene insertion (knock-in), gene deletion (knockout), and base editing, which entails the introduction of precise single-nucleotide alterations in DNA or RNA by the integration of CRISPR components with supplementary enzymes. Adenine base editors (ABEs) convert A–T pairs to G–C pairs, whereas cytosine base editors (CBEs) transform C–G pairs into T–A pairs in DNA base editing. Despite their adaptability, these tools encounter obstacles, including inadvertent alterations to nearby nucleotides and the necessity for tweaks to transpire within 15 nucleotides of a protospacer adjacent motif (PAM) sequence. RNA base editing comprises two systems: RESCUE, which promotes C-to-U transitions, and REPAIR, which enables A-to-I (G) conversions.

Cas9, the most extensively studied CRISPR nuclease, is commonly utilized for its efficiency and affordability in DNA modification. It functions by identifying target DNA sequences via complementary base pairing facilitated by RNA. Nevertheless, its dependence on the PAM sequence may constrain its adaptability in target site selection, and editing within operons could inadvertently interfere with the transcription of downstream genes. To mitigate these limitations, Cas13 has been engineered as a multifaceted RNA-editing instrument with fewer off-target effects relative to RNA interference (RNAi). The Cas13 family comprises six variants: Cas13a, Cas13b, Cas13c, Cas13d, Cas13X, and Cas13Y. Recent discoveries, such as the compact Cas13X and Cas13Y (775–803 amino acids), provide increased adaptability, with manufactured variants such as Cas13X.1 exhibiting great selectivity and effectiveness in RNA editing. The diversity and evolution of CRISPR-Cas systems are continually broadening the available tools for genome editing, presenting significant promise for researchers and physicians to enhance genetic modification technologies for practical use. Notwithstanding hurdles such as off-target effects and limitations in specificity, continuous developments indicate a hopeful future for CRISPR in scientific and medical domains.

RESULTS AND DISCUSSIONS

CRISPR-based genome editing technologies have advanced rapidly, providing exceptional precision and versatility in altering genetic material. The wild-type CRISPR-associated protein SpCas9 has been important to these achievements. Nonetheless, its propensity to induce double-stranded DNA breakage frequently results in unintended insertions or deletions (indels). To tackle this issue, researchers have created enhanced tools, including nickase Cas9 (nCas9), which generates single-stranded "nicks," and catalytically inactive Cas9 (dCas9), which attaches to DNA without inducing breaks. These advanced methods, in conjunction with DNA-modifying enzymes, provide accurate genomic modifications while minimizing off-target effects [3]. Among these breakthroughs, base editors, which combine nCas9 or dCas9 with deaminase enzymes, enable precise single nucleotide transformations, such as C-to-T or A-to-G, without inducing double-strand breaks. Although revolutionary, base editing is limited to a specific range of nucleotide alterations. Prime editing has mitigated these restrictions by combining nCas9 with a reverse transcriptase enzyme and a prime editing guide RNA (pegRNA). This advanced approach facilitates accurate insertion or replacement of genetic sequences and is anticipated to rectify around 89% of genetic abnormalities in humans, excluding larger anomalies such as whole gene duplications or deletions.

In addition to DNA, CRISPR technology has been modified for RNA editing. This approach employs Cas13b linked with an adenosine deaminase domain to effectuate adenosine-to-inosine modifications in RNA molecules. This RNA-centric approach, inherently reversible due to the transient nature of RNA, exhibits a safer treatment profile and holds considerable promise for targeting mutations associated with specific disorders [3]. A persistent difficulty in CRISPR applications is the effective delivery of these components to target cells. Adeno-associated viral (AAV) vectors are extensively utilized to deliver CRISPR components; nevertheless, the substantial size of wild-type SpCas9 imposes serious limitations on this method. To address this, researchers have developed smaller CRISPR enzymes, including *Axidiobacillus sulfuroxidans* Cas12f (AsCas12f). AsCas12f, exhibiting editing activity akin to SpCas9 although only one-third its size, has been effectively administered in mice via AAV vectors, underscoring its potential for therapeutic genome editing.

A significant challenge in utilizing CRISPR for clinical applications is ensuring the safe and effective delivery of CRISPR components to targeted tissues while minimizing unintended

off-target effects. Researchers are creating advanced delivery technologies, including modified adeno-associated viral (AAV) vectors, to tackle this issue. Researchers are currently conducting comprehensive testing in both in vitro and in vivo animal models to assess the accuracy and safety of these approaches [1]. Contemporary delivery methods for CRISPR-Cas systems can be categorized into viral vector-based tactics and non-viral carrier-based techniques. Viral vectors have benefits, although they also include hazards, including possible mutations, carcinogenesis, and immunological reactions upon integration into host cells. Nonetheless, recombinant AAVs, because of their non-replicating nature and predominant episomal presence, mitigate these hazards and infrequently incorporate into the genome. AAVs are particularly advantageous for delivering CRISPR components because of their cell-specific serotypes, lower immunogenicity relative to other viral vectors, and ability to facilitate temporary gene expression. Despite these benefits, issues with safety and efficiency remain.

Non-viral delivery technologies are under active development, with techniques like nanoparticles and liposomes demonstrating significant potential. Nanoparticles, composed of tailored lipids or polymers, improve cellular absorption, augment editing efficiency beyond mere protein delivery, and broaden target tissue accessibility beyond the liver. Moreover, they may elicit fewer immunological responses compared to viral vectors. A significant non-viral approach entails utilizing messenger RNA (mRNA) to encode CRISPR components. This method, akin to RNA vaccines, enables temporary and regulated gene editing without necessitating DNA delivery, hence minimizing related dangers [1]. The CRISPR system can also be utilized without direct in vivo administration. Ex vivo gene therapy entails the extraction of patient cells, their modification in a regulated laboratory setting, and subsequent reintegration into the organism. This technique has been effectively employed to address hereditary abnormalities, including sickle cell anemia, and to augment immune functions in cancer treatment. The various delivery and application approaches demonstrate ongoing endeavors to enhance CRISPR technology for secure, efficient, and adaptable therapeutic use.

Cardiovascular diseases (CVD) represent a significant global health issue, resulting in elevated morbidity and mortality rates. Advancements in genome editing, especially CRISPR-Cas systems, have empowered researchers to enhance their understanding, modeling, and treatment of different cardiovascular diseases by targeting genetic abnormalities linked with these conditions. These technologies have transformed both in vitro and in vivo research,

Received: 2024-09-09 Revised: 2025-01-10 Accepted: 2025-03-01 Published: 2025-06-30

offering insights into the genetic processes of cardiovascular disorders [20]. A primary application of genome editing in cardiovascular disease research is the creation of accurate disease models. Human-induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) are a crucial resource for investigating genetic alterations, pharmacological responses, and disease advancement. CRISPR technology has effectively been employed to introduce and rectify mutations in hiPSC-CMs, enabling researchers to investigate genes associated with disorders such as hypertrophic cardiomyopathy (HCM), dilated cardiomyopathy (DCM), and hereditary arrhythmias. By altering genes like DNMT3A, SCN10A, SPEG, and RRAD, scientists can learn more about how these genes affect heart disease.

In addition to modeling, genome editing possesses significant therapeutic potential for addressing monogenic cardiovascular disorders. Duchenne muscular dystrophy (DMD), frequently resulting in severe cardiomyopathy, has been a primary focus of CRISPR-mediated gene repair. Investigators have been using exon-skipping techniques and base editing to reinstate dystrophin expression in animal models, resulting in notable enhancements in heart function. Editing mutations in the Myh6 and TTN genes has demonstrated potential in the treatment of hypertrophic cardiomyopathy (HCM) and dilated cardiomyopathy (DCM), respectively. Prime editing and base editing approaches have significantly improved the accuracy of these therapies, positioning them as viable options for clinical application [2]. Genome editing techniques have also addressed arrhythmias, a significant category of cardiovascular disease. Researchers have investigated CRISPR-mediated allele-specific disruption as a method to rectify harmful mutations associated with arrhythmic diseases. Research on PLN-R14del mutations has demonstrated that genome editing can enhance heart function and diminish the risk of fatal arrhythmias.

Besides hereditary disorders, genome editing has been explored as a therapeutic approach for atherosclerosis. The inhibition of PCSK9, a gene that regulates LDL cholesterol levels, has been a primary emphasis in this domain. Research utilizing mice models has shown that CRISPR-Cas9-induced PCSK9 deletion results in a substantial decrease in LDL cholesterol, consequently diminishing the risk of atherosclerotic plaque development. These findings underscore the possibility of genome editing in mitigating cardiovascular illnesses by addressing metabolic risk factors [2]. Notwithstanding these achievements, numerous hurdles persist in the clinical translation of genome editing medicines. A significant obstacle is the

Received: 2024-09-09 Revised: 2025-01-10 Accepted: 2025-03-01 Published: 2025-06-30

secure and effective transport of genome editing elements to cardiac tissues. Adeno-associated virus (AAV)-mediated administration is the predominant technique employed; nonetheless, it is constrained by restrictions such as immunological responses and possible off-target consequences. Moreover, ethical issues pertaining to germline editing and inadvertent genetic alterations must be meticulously considered prior to the widespread implementation of genome editing in therapeutic settings. Prospectively, the ongoing enhancement of genome editing tools, such as prime editing and base editing, presents fresh promise for the management of cardiovascular disorders. As research progresses, genome editing could transform into a groundbreaking therapeutic approach, providing precise and lasting solutions for hereditary cardiac disorders. The integration of sophisticated delivery mechanisms, enhanced safety profiles, and stringent clinical validation will be crucial for achieving the complete promise of genome editing in cardiovascular therapy.

CONCLUSIONS

CRISPR technology has transformed gene editing by providing unmatched precision, efficiency, and cost-effectiveness relative to conventional techniques. Its utilization in cardiovascular diseases (CVD) has facilitated notable progress in disease modeling, mutation rectification, and prospective therapy strategies. CRISPR has demonstrated encouraging outcomes in treating monogenic cardiac ailments, atherosclerosis, and arrhythmias by accurately targeting mutations associated with these diseases. Innovations like base editing, prime editing, and RNA editing have augmented the precision and safety of genomic alterations, while the advancement of smaller CRISPR enzymes and sophisticated delivery systems has expanded therapeutic viability. Nonetheless, obstacles including off-target consequences, immunological reactions, and ethical dilemmas related to germline editing and clinical implementation persist. Ensuring regulatory supervision and mitigating these constraints are essential for the successful incorporation of CRISPR into medical practice. Future developments in genome editing technology, alongside improved delivery mechanisms and ethical considerations, promise to revolutionize the treatment of cardiovascular illnesses and facilitate the development of safer and more effective gene treatments.

Received: 2024-09-09 Revised: 2025-01-10 Accepted: 2025-03-01 Published: 2025-06-30

REFERENCES

- [1] H. T. Greely, "CRISPR'd babies: human germline genome editing in the 'He Jiankui affair,'" *J. Law Biosci.*, vol. 6, no. 1, pp. 111–183, 2019.
- [2] R. Barrangou, "CRISPR Milestones and Anticipating What Is Next for the Journal," 2021, *SAGE Publications Sage CA: Los Angeles, CA*.
- [3] R. Barrangou, "Commissions, Consensus, and CRISPR," *CRISPR J.*, vol. 3, no. 5, pp. 316–317, 2020.
- [4] Y. Higashikuni and T. K. Lu, "Advancing CRISPR-based programmable platforms beyond genome editing in mammalian cells," *ACS Synth. Biol.*, vol. 8, no. 12, pp. 2607–2619, 2019.